Latest News on COGT

Financial News Based On Company


Advertisement
Advertisement

COGT: Three FDA decisions ahead; launch infrastructure is ready for near-term approvals

https://www.tradingview.com/news/urn:summary_document_transcript:quartr.com:4662364:0-cogt-three-fda-decisions-ahead-launch-infrastructure-is-ready-for-near-term-approvals/
Cogent Biosciences (COGT) has three FDA decisions on the horizon, with PDUFA dates for GIST and non-advanced systemic mastocytosis in November and December 2026, respectively, and advanced disease targeted for June 2027. The company sees a significant $2.5 billion U.S. GIST market opportunity and states that launch preparations are well underway. This information is based on an AI-generated summary of their UBS Global Biopharma Conference 2026 audio transcript.

Cogent Biosciences stock hits 52-week low at 27.73 USD By Investing.com

https://uk.investing.com/news/stock-market-news/cogent-biosciences-stock-hits-52week-low-at-2773-usd-93CH-4985698
Cogent Biosciences stock has reached a 52-week low at $27.73, with shares dropping significantly over the past week and year-to-date. Despite the downturn, analysts maintain optimistic price targets, and the stock is considered undervalued by InvestingPro. Recent developments include the FDA's acceptance of a new drug application for bezuclastinib, supported by positive trial results, with a PDUFA date set for June 29, 2027.

Cogent Biosciences stock hits 52-week low at 27.73 USD By Investing.com

https://ca.investing.com/news/stock-market-news/cogent-biosciences-stock-hits-52week-low-at-2773-usd-93CH-4961691
Cogent Biosciences (COGT) stock has reached a new 52-week low of $27.73, marking a significant decline of nearly 15% in the past week and 20% year-to-date. Despite this downturn, analysts maintain optimistic price targets ranging from $45 to $61, suggesting the stock may be undervalued. The company recently saw its new drug application for bezuclastinib accepted by the FDA, with a PDUFA date in June 2027, and several firms have reiterated Buy ratings.

The Technical Signals Behind (COGT) That Institutions Follow

https://news.stocktradersdaily.com/news_release/24/The_Technical_Signals_Behind_COGT_That_Institutions_Follow_111526030202_1794729722.html
This article provides a technical analysis of Cogent Biosciences Inc. (NASDAQ: COGT), highlighting weak sentiment across all time horizons which supports a short bias for the stock. It details three AI-generated trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—each with specific entry, target, and stop-loss levels. The analysis also identifies support and resistance signals across near-term, mid-term, and long-term timeframes, all indicating a weak bias.

Losses Widen At Cogent Biosciences Stock Has The Bull Case Changed

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cogt/cogent-biosciences/news/losses-widen-at-cogent-biosciences-stock-has-the-bull-case-c
Cogent Biosciences reported wider net losses in Q3 2026 and for the nine-month period, totaling US$111.43 million and US$305.18 million respectively, driven by high R&D and overhead costs without matching revenue. The article highlights that the investment narrative for Cogent Biosciences hinges on its precision therapy pipeline, especially bezuclastinib, successfully transitioning from research to commercial products. The increasing losses raise concerns about funding and capital access, particularly as the company reports virtually no revenue.
Advertisement

HC Wainwright & Co. maintains Cogent Biosciences at Buy, raises price target to $56 from $55

https://www.tradingview.com/news/tradingview:fe17507425c77:0-hc-wainwright-co-maintains-cogent-biosciences-at-buy-raises-price-target-to-56-from-55/
HC Wainwright & Co. has reiterated its "Buy" rating for Cogent Biosciences (COGT) and increased its price target from $55 to $56. This new price target suggests a potential upside of 77.0% from the stock's closing price of $31.64 on November 6. The report highlights the firm's continued confidence in the company's prospects.

Cogent Biosciences, Inc. (COGT) stock price, news, quote and history

https://sg.finance.yahoo.com/quote/COGT/
Cogent Biosciences, Inc. (COGT) stock closed at $31.65, up 6.98% on November 6th. The company, a clinical-stage biotechnology firm, focuses on developing precision therapies for genetically defined diseases, with lead product candidates including bezuclastinib in Phase 3 for systemic mastocytosis and GIST. Analysts have an average target price of $55.82 for COGT, with a "Strong Buy" recommendation.

Cogent Biosciences, Inc. (COGT) stock price, news, quote and history

https://au.finance.yahoo.com/quote/COGT/
This Yahoo Finance page provides a detailed overview of Cogent Biosciences, Inc. (COGT) stock, including its current price, performance metrics, and key financial data. It also outlines the company's business in developing precision therapies for genetically defined diseases, highlighting its lead product candidate bezuclastinib and other pipeline assets. The page includes analyst ratings, earnings trends, and valuation measures for investors.

Cogent Biosciences (COGT) Could Be 89% Undervalued On Wider Third Quarter Losses

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cogt/cogent-biosciences/news/cogent-biosciences-cogt-could-be-89-undervalued-on-wider-thi
Cogent Biosciences (COGT) reported wider third-quarter 2026 losses, reaching US$111.43 million, yet a Discounted Cash Flow (DCF) model suggests the stock might be significantly undervalued by 89% compared to its estimated future cash flow value of $268.29. The company's share price fell by 6.07% on the day and 30.22% over 90 days, despite a 99.60% one-year gain, while its price-to-book (P/B) ratio of 11x is considered high relative to industry averages. Investors face mixed signals, balancing the high P/B valuation with the DCF model's deep undervaluation, highlighting both potential opportunities and risks linked to trial outcomes and financial performance.

Cogent Biosciences Reports Recent Business Highlights and Third Quarter 2026 Financial Results

https://www.globenewswire.com/news-release/2026/11/05/3396995/0/en/cogent-biosciences-reports-recent-business-highlights-and-third-quarter-2026-financial-results.html
Cogent Biosciences reported its third-quarter 2026 financial results, highlighting preparations for the anticipated launch of bezuclastinib in GIST and other systemic mastocytosis indications. The company has a strong cash balance of $791.1 million, expected to fund operations into late 2028, and plans to present new data at the American Society of Hematology meeting. They also announced the initiation of an extension cohort for the PEAK trial and the FDA's acceptance of the NDA for bezuclastinib in Advanced Systemic Mastocytosis.
Advertisement

With $791M in cash and securities, Cogent Biosciences (COGT) posts a wider quarterly loss.

https://www.stocktitan.net/sec-filings/COGT/8-k-cogent-biosciences-inc-reports-material-event-9f7b89fe8507.html
Cogent Biosciences reported a wider net loss of $111.4 million for the third quarter of 2026, compared to $80.9 million a year prior, primarily due to increased research and development and general and administrative expenses. Despite the loss, the company holds $791.1 million in cash and securities, which it expects to fund operations into late 2028, beyond three upcoming PDUFA dates for its drug bezuclastinib. Cogent is actively preparing for the potential launch of bezuclastinib in GIST and other indications while also advancing new pipeline programs.

Cogent Biosciences Reports Recent Business Highlights and Third Quarter 2026 Financial Results

https://www.stocktitan.net/news/COGT/cogent-biosciences-reports-recent-business-highlights-and-third-gt1esw1geo5o.html
Cogent Biosciences reported its third-quarter 2026 financial results, with a widened net loss of $111.4 million, up from $80.9 million a year prior. The company is preparing for potential FDA approvals and commercial launch of bezuclastinib for GIST and Systemic Mastocytosis, with target action dates spanning November 2026 through June 2027. Cogent anticipates its $791.1 million cash reserves will fund operations into late 2028, and it plans to present new clinical data at the ASH meeting in December 2026.

Cogent Biosciences Reports Recent Business Highlights and Third Quarter 2026 Financial Results

https://investingnews.com/cogent-biosciences-reports-recent-business-highlights-and-third-quarter-2026-financial-results/
Cogent Biosciences announced recent business highlights and financial results for the third quarter of 2026, ahead of anticipated launches for bezuclastinib in GIST and potential approvals in NonAdvanced and Advanced Systemic Mastocytosis. The company reported a cash balance of $791.1 million, expected to fund operations into late 2028, and a net loss of $111.4 million for the quarter. Cogent also plans to present new data on bezuclastinib at the ASH 2026 meeting and submit IND applications for new pipeline programs.

(COGT) and the Role of Price-Sensitive Allocations

https://news.stocktradersdaily.com/news_release/91/COGT_and_the_Role_of_Price-Sensitive_Allocations_110526032602_1793867162.html
This article provides an in-depth analysis of Cogent Biosciences Inc. (NASDAQ: COGT) based on AI-generated signals and institutional trading strategies. It highlights conflicting sentiment across different time horizons, suggesting choppy market conditions, and outlines specific position trading, momentum breakout, and risk hedging strategies. The analysis also details support and resistance levels for near-term, mid-term, and long-term perspectives.

Cogent Biosciences, Inc. (COGT) Seasonal Returns Chart - Yahoo Finance

https://ca.finance.yahoo.com/quote/COGT/seasonality/
The article provides a seasonal returns chart for Cogent Biosciences, Inc. (COGT), displaying the average monthly price return from 2018 to 2026. It includes current stock data, showing a closing price of $31.02 and an after-hours price of $31.30 as of October 30. The page primarily focuses on the stock's seasonality data within a Yahoo Finance context.
Advertisement

Analysts Offer Insights on Healthcare Companies: Cogent Biosciences (COGT), Merck & Company (MRK) and Alnylam Pharma (ALNY)

https://www.theglobeandmail.com/investing/markets/stocks/MRK/pressreleases/8501068/analysts-offer-insights-on-healthcare-companies-cogent-biosciences-cogt-merck-company-mrk-and-alnylam-pharma-alny/
This article provides an overview of recent analyst ratings for three healthcare companies: Cogent Biosciences (COGT), Merck & Company (MRK), and Alnylam Pharma (ALNY). Stifel Nicolaus maintained a Buy rating for Cogent Biosciences, RBC Capital a Hold rating for Merck & Company, and BMO Capital a Buy rating for Alnylam Pharma, all with specific price targets and consensus ratings highlighted. The report includes details about the analysts' track records and the potential upside for each stock.

Stifel Maintains Cogent Biosciences(COGT.US) With Buy Rating, Maintains Target Price $45

https://www.moomoo.com/news/post/1002505774/stifel-maintains-cogent-biosciences-cogtus-with-buy-rating-maintains-target
Stifel has reiterated its Buy rating on Cogent Biosciences (COGT.US) and maintained its target price of $45. This reflects a continued positive outlook from the firm regarding the biotechnology company.

Cogent Biosciences to Participate in the Guggenheim Healthcare Innovation Conference

https://investingnews.com/cogent-biosciences-to-participate-in-the-guggenheim-healthcare-innovation-conference/
Cogent Biosciences (Nasdaq: COGT) will participate in a fireside chat at the Guggenheim 3rd Annual Healthcare Innovation Conference on November 10, 2026, at 7:30 a.m. ET. The company also announced "inducement" equity awards granted to six new employees on October 26, 2026, consisting of nonqualified options and restricted stock units. These awards are in line with Nasdaq Listing Rule 5635(c)(4) and are designed to vest over four years.

Cogent Biosciences to Participate in the Guggenheim Healthcare Innovation Conference

https://www.globenewswire.com/news-release/2026/10/27/3389587/0/en/cogent-biosciences-to-participate-in-the-guggenheim-healthcare-innovation-conference.html
Cogent Biosciences announced its participation in the Guggenheim 3rd Annual Healthcare Innovation Conference, where it will hold a fireside chat on November 10, 2026, at 7:30 a.m. ET. The company also disclosed that its Compensation Committee approved inducement equity awards for six new employees, including nonqualified options and restricted stock units, in accordance with Nasdaq Listing Rule 5635(c)(4). These awards, granted on October 26, 2026, are part of the company's efforts to develop precision therapies for genetically defined diseases.

Cogent Biosciences, Inc. Estimates – NASDAQ:COGT

https://www.tradingview.com/symbols/NASDAQ-COGT/financials-estimates/
This article provides an overview of Cogent Biosciences, Inc. (NASDAQ: COGT) financial data and analyst estimates available on TradingView. It directs users to explore reported financial data and compare actual results with average, high, and low estimates across various financial statements. The content focuses on fundamental analysis tools for investors.
Advertisement

If You Invested $1000 In Cogent Biosciences Stock 5 Years Ago, You Would Have This Much Today

https://www.benzinga.com/news/26/10/62504149/if-you-invested-1000-cogent-biosciences-stock-5-years-ago-you-would-have-much-today
Cogent Biosciences (NASDAQ: COGT) has significantly outperformed the market over the past five years, generating an average annual return of 30.65%. An initial investment of $1000 in COGT stock five years ago would now be worth $3,787.77, demonstrating the power of compounded returns. The company currently holds a market capitalization of $5.21 billion.

Did FDA Filings Just Shift Cogent Biosciences Stock Investment Narrative?

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cogt/cogent-biosciences/news/did-fda-filings-just-shift-cogent-biosciences-stock-investme/amp
Cogent Biosciences' investment narrative is heavily focused on bezuclastinib, with three recent FDA filings for different indications, including gastrointestinal stromal tumors (GIST), drawing significant attention. The GIST application is viewed as having an above-average approval outlook, making upcoming FDA decisions crucial for the pre-revenue company. The stock's recent pullback suggests the market is already treating these 2026-2027 FDA catalysts as a major swing factor.

Technical Reactions to COGT Trends in Macro Strategies

https://news.stocktradersdaily.com/news_release/39/Technical_Reactions_to_COGT_Trends_in_Macro_Strategies_101526064202_1792104122.html
This article provides a technical analysis of Cogent Biosciences Inc. (NASDAQ: COGT), highlighting weak near and mid-term sentiment despite a positive long-term outlook. It presents proprietary signals and three distinct AI-generated trading strategies (Position, Momentum Breakout, and Risk Hedging) with specific entry, target, and stop-loss zones. The analysis also includes a multi-timeframe signal breakdown for the stock.

UBS Maintains Cogent Biosciences(COGT.US) With Buy Rating, Maintains Target Price $60

https://www.moomoo.com/news/post/1001158000/ubs-maintains-cogent-biosciences-cogtus-with-buy-rating-maintains-target
UBS has reiterated its Buy rating on Cogent Biosciences (COGT.US) and maintained its price target at $60. This indicates a continued positive outlook from the firm regarding the company's stock performance.

Here’s How Much You Would Have Made Owning Cogent Biosciences Stock In The Last 5 Years

https://www.benzinga.com/news/26/10/62312879/here-s-how-much-you-would-have-made-owning-cogent-biosciences-stock-last-5-years
Cogent Biosciences (NASDAQ: COGT) has significantly outperformed the market over the last five years, with an annualized return of 26.37%. An initial investment of $1000 in COGT five years ago would now be worth $3,244.01. The article highlights the substantial impact of compounded returns on cash growth over time.
Advertisement

Cogent Biosciences Inc. Research & Ratings | COGT

https://www.barrons.com/market-data/stocks/cogt/research-ratings?gaa_at=eafs&gaa_n=AWEtsqda378-vBiPTHtk94vHD9sMtP4wHndKNlqrwi2R0J6z-XYJiH52emwW&gaa_ts=69d52197&gaa_sig=z9mvEEUYDYwDFLbhRjgzd0WXiOGTlP2Ne0STKoamCVrXzUAif8d6koMnBafiy1RRjBFI-thdh9XiTH6orPz-Ug%253D%253D&mod=quotes
This article provides research and ratings for Cogent Biosciences Inc. (COGT), a biotechnology company specializing in therapies for genetically defined diseases. It includes analyst ratings, stock grader information, financial data such as market value and EPS, and quarterly and yearly earnings estimates. The consensus among analysts is a "Buy" with an average price target of $55.82.

Cogent Biosciences Inc. Company & People | COGT

https://www.barrons.com/market-data/stocks/cogt/company-people?gaa_at=eafs&gaa_n=AWEtsqda378-vBiPTHtk94vHD9sMtP4wHndKNlqrwi2R0J6z-XYJiH52emwW&gaa_ts=69d52197&gaa_sig=z9mvEEUYDYwDFLbhRjgzd0WXiOGTlP2Ne0STKoamCVrXzUAif8d6koMnBafiy1RRjBFI-thdh9XiTH6orPz-Ug%253D%253D
Cogent Biosciences Inc. (COGT) is a biotechnology company focused on developing precision therapies for genetically defined diseases, particularly through its drug CGT9486. The company's stock currently has an average analyst price target of $55.82 with an average "Hold" score, and key financial metrics like P/E Ratio and Dividend Yield are not applicable. The article provides detailed company information, including key executives, financial ratios, and stock performance data.

Taking options instead of cash, a Cogent Biosciences (COGT) director receives a 759-option award.

https://www.stocktitan.net/sec-filings/COGT/form-4-cogent-biosciences-inc-insider-trading-activity-5dcac4150788.html
Karen Jean Ferrante, a director at Cogent Biosciences (COGT), received an award of 759 stock options on October 1, 2026, as she elected to take shares instead of cash compensation for her director services. The options have an exercise price of $31.59 per share and are set to expire on October 1, 2036. The number of options was determined by dividing her quarterly cash compensation by the Black-Scholes value of a single option on the grant date.

$1000 Invested In Cogent Biosciences 5 Years Ago Would Be Worth This Much Today

https://www.benzinga.com/news/26/10/62150052/1000-invested-cogent-biosciences-5-years-ago-would-be-worth-much-today
Cogent Biosciences (NASDAQ: COGT) has significantly outperformed the market over the past five years, achieving an average annual return of 28.63%. An initial investment of $1,000 in COGT five years ago would now be valued at $3,577.85, highlighting the power of compounded returns. The company currently holds a market capitalization of $5.38 billion.

Cogent Biosciences Inc (COGT-Q) Stock Price and News

https://www.theglobeandmail.com/investing/markets/stocks/COGT/
This article provides stock price and news for Cogent Biosciences Inc. (COGT-Q), including recent analyst ratings, announcements of new drug application submissions, and detailed clinical data presentations. The company, focused on developing precision therapies, has seen significant news regarding its drug bezuclastinib for advanced systemic mastocytosis and gastrointestinal stromal tumors.
Advertisement

Insiders At Cogent Biosciences Sold US$12m In Stock, Alluding To Potential Weakness

https://www.moomoo.com/news/post/1000452704/insiders-at-cogent-biosciences-sold-us-12m-in-stock-alluding
Insiders at Cogent Biosciences have sold US$12 million worth of stock over the last year, suggesting they believe the stock may be overvalued. While insider buying can be a positive signal, significant insider selling often indicates a lack of confidence in the company's future performance. This raises questions about the company's prospects despite a lack of recent large individual purchases.

Why (COGT) Price Action Is Critical for Tactical Trading

https://news.stocktradersdaily.com/news_release/141/Why_COGT_Price_Action_Is_Critical_for_Tactical_Trading_092526055402_1790330042.html
This article analyzes Cogent Biosciences Inc. (NASDAQ: COGT) focusing on its price action for tactical trading. It highlights weak near and mid-term sentiment potentially challenging a long-term positive outlook, with no clear price positioning signal and elevated downside risk. The article also outlines three AI-generated institutional trading strategies (Position Trading, Momentum Breakout, and Risk Hedging) tailored for different risk profiles and holding periods, along with multi-timeframe signal analysis.

Cogent Biosciences, Inc. (COGT) Stock Price, News, Quote & History

https://ca.finance.yahoo.com/quote/COGT/
Cogent Biosciences, Inc. (COGT) is a clinical-stage biotechnology company focused on developing precision therapies for genetically defined diseases. The article provides current stock information, including its price, recent performance, key financial metrics, and an overview of its product pipeline like bezuclastinib and CGT4859. It also details analyst recommendations and company financials, positioning COGT as a developer of therapies for conditions like systemic mastocytosis and advanced gastrointestinal stromal tumors.

Cogent Biosciences (COGT) Looks Fully Valued Following FDA NDA Acceptance

https://finance.yahoo.com/healthcare/articles/cogent-biosciences-cogt-looks-fully-181215815.html
Cogent Biosciences (COGT) recently received FDA acceptance for its New Drug Application for bezuclastinib, but its shares have declined over the past 30 and 90 days. Despite a 137.1% one-year return, the company's valuation appears stretched with a 11.7x Price-to-Book multiple compared to the industry average of 2.2x, given its unprofitability, lack of meaningful revenue, and shareholder dilution. Investors are paying for future pipeline potential, but the stock carries risks including continued losses and dilution.

Cogent Biosciences (COGT) Stock Price, News & Analysis

https://www.stocktitan.net/overview/COGT/
Cogent Biosciences (COGT) is a biotechnology company focused on developing precision therapies for genetically defined diseases, with its lead candidate, bezuclastinib, targeting systemic mastocytosis and GIST. The company has reported positive results from its SUMMIT, APEX, and PEAK pivotal trials and has upcoming FDA PDUFA decisions for bezuclastinib in various indications. COGT's stock has shown a 160.8% gain over the past year, and it continues to expand its pipeline beyond bezuclastinib.
Advertisement

Should FDA Filing Acceptance Require Action From Cogent Biosciences Stock Investors?

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cogt/cogent-biosciences/news/should-fda-filing-acceptance-require-action-from-cogent-bios
Cogent Biosciences received FDA acceptance for its New Drug Application (NDA) for bezuclastinib in advanced systemic mastocytosis, with a PDUFA date of June 29, 2027, and no advisory committee or review issues indicated. The NDA is based on positive APEX trial data, showing high overall response rates. Despite strong past stock performance, the company is still pre-revenue, emphasizing the importance of managing burn rate, capital access, and potential dilution as it focuses on commercial launch preparations for its lead therapy.

Cogent Bio wins third FDA review for lead asset (COGT:NASDAQ)

https://seekingalpha.com/news/4642917-cogent-bio-wins-third-fda-review-lead-asset
Cogent Biosciences (COGT) has received FDA acceptance for its marketing application for bezuclastinib, its lead candidate, for a rare form of blood cancer. This marks the third indication for which the tyrosine kinase inhibitor is under regulatory review. The company had announced this development on Tuesday.

Cogent Biosciences Announces FDA Acceptance of New Drug Application (NDA) for Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)

https://finance.yahoo.com/healthcare/articles/cogent-biosciences-announces-fda-acceptance-120000587.html
Cogent Biosciences announced that the FDA has accepted its New Drug Application (NDA) for bezuclastinib to treat Advanced Systemic Mastocytosis (AdvSM), setting a PDUFA target action date of June 29, 2027. This acceptance is supported by positive results from the APEX pivotal trial, which showed clinically meaningful responses and durable activity in AdvSM patients. The company also has NDAs under review for NonAdvSM and GIST, with PDUFA dates in late 2026, aiming to bring bezuclastinib to market for multiple KIT-driven diseases.

Cogent Biosciences Announces FDA Acceptance of New Drug Application for Bezuclastinib in Patients with Advanced Systemic Mastocytosis

https://investingnews.com/cogent-biosciences-announces-fda-acceptance-of-new-drug-application-for-bezuclastinib-in-patients-with-advanced-systemic-mastocytosis/
Cogent Biosciences announced that the FDA has accepted its New Drug Application (NDA) for bezuclastinib to treat Advanced Systemic Mastocytosis (AdvSM), setting a PDUFA target action date of June 29, 2027. This NDA acceptance is based on positive results from the APEX pivotal trial, which showed clinically meaningful and durable responses in AdvSM patients. The company is also advancing NDAs for bezuclastinib in NonAdvanced Systemic Mastocytosis and GIST, with target action dates in late 2026.

Cogent Biosciences Announces FDA Acceptance of New Drug Application (NDA) for Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)

https://au.finance.yahoo.com/news/cogent-biosciences-announces-fda-acceptance-120000587.html
Cogent Biosciences announced that the FDA has accepted its New Drug Application (NDA) for bezuclastinib to treat Advanced Systemic Mastocytosis (AdvSM), setting a PDUFA target action date of June 29, 2027. The acceptance is based on positive results from the APEX pivotal trial, which showed significant and durable clinical responses in AdvSM patients. This marks another key regulatory step for bezuclastinib, with other NDAs already under review for NonAdvSM and GIST.
Advertisement

Cogent Biosciences Announces FDA Acceptance of New Drug

https://www.globenewswire.com/news-release/2026/09/15/3361988/0/en/cogent-biosciences-announces-fda-acceptance-of-new-drug-application-nda-for-bezuclastinib-in-patients-with-advanced-systemic-mastocytosis-advsm.html
Cogent Biosciences announced that the FDA has accepted its New Drug Application (NDA) for bezuclastinib to treat Advanced Systemic Mastocytosis (AdvSM), setting a PDUFA target action date of June 29, 2027. This acceptance is supported by positive data from the APEX pivotal trial, which showed significant response rates and durable clinical activity. The company is also pursuing regulatory approvals for bezuclastinib for NonAdvSM and GIST, with PDUFA dates in late 2026.

Liquidity Mapping Around (COGT) Price Events

https://news.stocktradersdaily.com/news_release/35/Liquidity_Mapping_Around_COGT_Price_Events_091426085801_1789433882.html
The article provides a liquidity mapping analysis for Cogent Biosciences Inc. (NASDAQ: COGT), highlighting weak near and mid-term sentiment but a strong long-term positive outlook. It identifies key support and resistance levels and outlines three AI-generated institutional trading strategies tailored for different risk profiles, emphasizing an exceptional 85.3:1 risk-reward setup.

A drug trial found responses in 65% of patients. The FDA will review it.

https://www.stocktitan.net/news/COGT/cogent-biosciences-announces-fda-acceptance-of-new-drug-application-puivgqb26usj.html
Cogent Biosciences announced that the FDA has accepted its New Drug Application (NDA) for bezuclastinib to treat Advanced Systemic Mastocytosis (AdvSM), setting a PDUFA target action date of June 29, 2027. This acceptance is supported by strong data from the APEX pivotal trial, which showed a 65% overall response rate in AdvSM patients. The company also has two other bezuclastinib NDAs under FDA review for NonAdvSM and GIST, with PDUFA dates in late 2026, and has established expanded access programs for eligible U.S. patients.

Cogent Biosciences director Arlene Morris sells $1.69m shares By Investing.com

https://au.investing.com/news/stock-market-news/cogent-biosciences-director-arlene-morris-sells-169m-shares-93CH-4623477
Cogent Biosciences director Arlene Morris sold approximately $1.69 million in company shares on August 27, 2026, through a pre-arranged trading plan, after exercising stock options on the same day. Despite the sale, analysts remain bullish on Cogent Biosciences, with price targets ranging from $45 to $62, citing positive clinical trial results for bezuclastinib and an upcoming FDA decision. The company's stock has shown impressive growth, up 189% over the past year, and it maintains strong liquid assets.

What Cogent Biosciences (COGT)'s Widening Net Losses Mean For Shareholders

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cogt/cogent-biosciences/news/what-cogent-biosciences-cogts-widening-net-losses-mean-for-s
Cogent Biosciences reported widening net losses for Q2 and the half-year 2026, reaching US$96.41 million and US$193.76 million respectively, indicating increased investment in development. While these losses reinforce its pre-revenue, high-spend status, they don't change the near-term catalysts, such as upcoming FDA PDUFA dates for bezuclastinib. However, the higher cash burn raises concerns about financing conditions, potential dilution, and the company's ability to fund its pipeline, potentially affecting its valuation.
Advertisement

H.C. Wainwright Maintains Cogent Biosciences(COGT.US) With Buy Rating, Maintains Target Price $55

https://www.moomoo.com/news/post/74947311/hc-wainwright-maintains-cogent-biosciences-cogtus-with-buy-rating-maintains
H.C. Wainwright has reiterated its Buy rating on Cogent Biosciences (COGT.US), maintaining a target price of $55. This continued positive outlook suggests confidence in the company's prospects.

Has Cogent Biosciences (COGT) Run Too Far After Wider Losses?

https://www.sahmcapital.com/news/content/has-cogent-biosciences-cogt-run-too-far-after-wider-losses-2026-08-17
Cogent Biosciences (COGT) recently reported wider losses in Q2 2026, with a net loss of US$96.41 million. Despite a strong 213.21% total shareholder return over the past year, recent momentum has cooled, and the stock's high price-to-book ratio of 14.1x suggests a premium valuation, justified by its peer group but carrying risks related to clinical trials and ongoing losses. The article advises investors to consider the company's future execution and potential risks.

COGT Maintained by Piper Sandler -- Price Target Raised to $55

https://www.gurufocus.com/news/9038877/cogt-maintained-by-piper-sandler-price-target-raised-to-55
Piper Sandler has maintained an "Overweight" rating for Cogent Biosciences (COGT) and raised its price target to $55.00, reflecting increased confidence in the company's potential, especially for its precision therapy program CGT9486. Despite this positive analyst outlook, Cogent Biosciences has a low GF Score™ of 30/100 and a high Price-to-Sales ratio of 220.78x, indicating potential overvaluation and challenges in profitability and growth, suggesting investors should proceed with caution.

Has Cogent Biosciences (COGT) Run Too Far After Wider Losses?

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cogt/cogent-biosciences/news/has-cogent-biosciences-cogt-run-too-far-after-wider-losses
Cogent Biosciences (COGT) recently reported wider net losses for Q2 and H1 2026, with a net loss of US$96.41 million for the quarter and US$193.76 million for the half-year. Despite a strong 213.21% total shareholder return over the past year, its 90-day share price return of 21.38% and a recent 7-day decline suggest momentum is cooling. The company's Price-to-Book ratio of 14.1x is high compared to the broader biotech industry but aligns with its closer peers, indicating investors are weighing future pipeline execution and expected revenue growth over current financials.

Why Cogent Biosciences (COGT) Is Down 10.5% After Reporting Wider First-Half 2026 Losses – And What's Next

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cogt/cogent-biosciences/news/why-cogent-biosciences-cogt-is-down-105-after-reporting-wide
Cogent Biosciences (COGT) reported wider net losses for Q2 and H1 2026, leading to a 10.5% stock drop. The company's investment narrative is currently focused on cash burn and funding, with future catalysts tied to FDA reviews for bezuclastinib and launch preparedness. Investors are advised to consider the implications of sustained losses on future funding and the company's valuation.
Advertisement
Advertisement
Advertisement
Advertisement

Sign Up free to view live trades and discussion forum to make more informed financial decisions. No credit card is required for sign up!
View Daily Trades
Join Discussion

Advertisement
Advertisement
Advertisement
Advertisement